Genovare Peptides | Retatrutide 60 mg Pen

Genovare Peptides | Retatrutide 60 mg PenRetatrutide (LY3437943) is a synthetic acylated peptide analogue functioning as a triple agonist at the glucagon like peptide 1 (GLP 1), glucose dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors simultaneously. This tri receptor agonism distinguishes it from dual agonists such as tirzepatide (GLP 1 GIP) and single agonists such as semaglutide (GLP 1). By engaging all three receptors, retatrutide is studied for its combined

Retatrutide (LY3437943) is a synthetic acylated peptide analogue functioning as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors simultaneously. This tri-receptor agonism distinguishes it from dual agonists such as tirzepatide (GLP-1/GIP) and single agonists such as semaglutide (GLP-1). By engaging all three receptors, retatrutide is studied for its combined ability to suppress appetite via GLP-1 signalling, enhance insulin secretion and fat metabolism via GIP signalling, and increase energy expenditure via glucagon receptor activation. Phase 2 clinical trial data has demonstrated significant reductions in body weight and metabolic markers.

How It Is Used Retatrutide is supplied as a lyophilised peptide, reconstituted with bacteriostatic water, and administered via subcutaneous injection. Research applications include metabolic syndrome modelling, obesity pharmacology, insulin resistance studies, and hepatic fat regulation.